Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering AG/Epix Vasovist (MS-325)

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA is asking Epix "to consider a re-read of the images from the Phase III trials to provide additional information about the usefulness of dynamic versus steady state images, and to schedule a meeting with the FDA to discuss the merits and design of such a study," the company says July 1. The firm announced that FDA accepted its May 23 "complete response" to a January "approvable" letter, setting a user fee goal date of Nov. 23. However, "Epix' response did not include efficacy data from new clinical trials, which were requested by the FDA to demonstrate efficacy prior to approval in the…approvable letter," Epix explained. CEO Michael Webb acknowledged that Epix is "not yet in agreement with the FDA," but has maintained that the complete response addresses the agency's concerns (1Pharmaceutical Approvals Monthly June 2005, p. 5)...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002975

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel